A Phase 1 Basket Study Evaluating the Safety and Feasibility of T Plex, Autologous Customized T Cell Receptor Engineered T Cells Targeting Multiple Peptide/HLAAntigens in Participants with Antigen positive Locally Advanced (Unresectable) or Metastatic Solid Tumors
Study of T Plex in Patients with Advanced or Metastatic Solid Tumors
Sponsor: TScan Therapeutics, Inc
Enrolling: Male and Female Patients
IRB Number: AAAU7036
U.S. Govt. ID: NCT05973487
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of the study is to learn if the study treatments TSC-204-A0201, TSC 200-A020, and TSC-204-C0702 alone or in combination, referred to as T-Plex, are safe and effective in treating your type of cancer. T-Plex has not yet been approved by the Food and Drug Administration (FDA). This is a first-in-human study, which means that these products have never been administered to humans before. You are unlikely to benefit from taking part in this study. Cancers include: Colon and Rectal Cancer, Lung Cancer, Cervical Cancer, Ovarian Cancer, Head and Neck/Oral Cancers, Melanoma, and Testicular Cancer.
Brian Henick, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Have you been diagnosed with an advanced (unresectable) or metastatic solid tumor? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator